Not yet recruitingPHASE1, PHASE2NCT07131345
Study of Iparomlimab and Tuvonralimab Plus Chemotherapy in Malignant Mesothelioma
Studying Pleural mesothelioma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Center, China
- Principal Investigator
- Puyuan Xing, MD, M.D., Ph.DNational Cancer Center, China
- Intervention
- iparomlimab and tuvonralimab (Dual PD-1/CTLA-4 blockade) + chemotherapy(drug)
- Enrollment
- 55 enrolled
- Eligibility
- 18-75 years · All sexes
- Timeline
- 2025 – 2027
Collaborators
Qilu Pharmaceutical Co., Ltd. · Affiliated Cancer Hospital of Zhengzhou University · Beijing Chest Hospital, Capital Medical University · The Affiliated Hospital of Inner Mongolia Medical University · Shaanxi Provincial Cancer Hospital
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07131345 on ClinicalTrials.govOther trials for Pleural mesothelioma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1NCT07532902A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor CancerMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1NCT07192900Fast TILs to Treat Metastatic Cancer Patients With Pleural DiseaseDavid Bartlett, MD
- RECRUITINGPHASE1NCT07443020Fast TILs to Treat Metastatic Pleural Effusions From Epithelial or Mesothelial Primary TumorsAllegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
- RECRUITINGNANCT07126509Partial Pleurectomy (Surgery) for Unresectable Pleural MesotheliomaUniversity of Chicago
- RECRUITINGPHASE1, PHASE2NCT07121374NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility StudyUniversity Hospital, Antwerp
- RECRUITINGPHASE1NCT06885697Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including MesotheliomaNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT06840834Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and ChemotherapyIntergroupe Francophone de Cancerologie Thoracique
- RECRUITINGPHASE2NCT06875076Multicenter Single-Arm Study of Ivonescimab (AK112) Combined with Chemotherapy in Pretreated Pleural MesotheliomaThe First Hospital of Jilin University